People
Life science and pharma companies strengthen their leadership teams with this week’s appointments.
According to the 2019 BioSpace Ideal Employer Report, health benefits are now one of the top three most important attributes life science professionals consider when looking for an employer.
Retrophin, Inc. announced the appointment of Peter Heerma as chief commercial officer, effective immediately.
The Indiana Health Industry Forum is pleased to announce Representative Jackie Walorski as the group’s 2019 Legislator of the Year.
After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers has resigned from his role as head of research and development.
According to multiple reports, President Donald Trump is set to pick Hahn, a noted radiation oncologist, as the successor to Scott Gottlieb.
Solentim, the global leader in cell line development instrumentation, is delighted to announce that Dr Mark Truesdale will join the Company as the new Chief Marketing Officer, effective immediately.
Assertio Therapeutics, Inc. announced that Dr. David Wheadon has been appointed to the Company’s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc.
Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board.
4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces that it has appointed Philippe Fauchet, OBE, as a Venture Partner based in Japan.
PRESS RELEASES